Dermal and systemic side effects of fluocortin butylester. Comparative skin tearing experiments with active principles from commercial preparations
Kapp, J.F.; Gliwitzki, B.; Josefiuk, P.; Weishaupt, W.
Arzneimittel-Forschung 27(11a): 2206-2213
1977
ISSN/ISBN: 0004-4172 PMID: 580030 Document Number: 111159
Different concentrations of butyl 6alpha-fluoro-11beta-hydroxy-16alpha-methyl-3,20-dioxo-1,4-pregnadien-21-oate (fluocortin butylester FCB, Vaspit) and of clobetasone-17-butyrate, clobetasole-17-propionate and hydrocortisone-17-butyrate have been administered topically in order to investigate dermal and systemic side effects. It could be shown that FCB exhibits by far the least side effects. A specially devised apparatus covering the site of substance application, guaranteed an exclusive dermal absorption. Side effects, therefore, cannot be ascribed to oral ingestion of the drugs.